Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Umeclidinium for Primary Axillary Hyperhidrosis
NCT02563899Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of umeclidinium in primary axillary hyperhidrosis (PAH), sponsored by GSK. Started Nov 2015; status: completed.
02
Drugs
umeclidinium
03
Conditions
primary axillary hyperhidrosis (PAH)
Beyond the preview
Go deeper on NCT02563899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563899.